## Oregon EIP Candidemia Surveillance



## December 2019 Surveillance Summary

The Oregon Emerging Infection Program (EIP) conducts laboratory and population-based surveillance for *Candida* spp. Bloodstream infections among residents of the tri-county (Clackamas, Multnomah, and Washington) Portland metropolitan area (2012 estimated population: 1,672,970). Oregon is one of four EIP sites participating in this surveillance project, with these objectives:

- To determine how many Candida bloodstream infections occurred in the surveillance area
- To describe people at risk for Candida bloodstream infections
- To identify which types of Candida cause illness
- To reveal trends of drug resistance

For more information about the EIP Candidemia surveillance project, see http://www.cdc.gov/hai/eip/candida.html



Portland tri-county candidemia cases by age and sex, Dec 2019							
_	Female		Male		Deaths	Total	
Age group	n	%	n	%	n		
<5	4	1.2	14	1.8	0	18	
5–17	6	1.2	7	2.0	3	13	
18–34	60	10.2	36	7.1	2	96	
35–49	61	8.4	45	7.3	14	106	
50–64	90	19.3	123	19.4	50	213	
65–79	73	11.0	55	8.0	48	128	
≥80	20	2.4	36	6.3	18	56	
Total	314		316		135	630*	

Date

Since surveillance began in January 2011, 636 patients with *Candida* bloodstream infections have been reported in the Portland metropolitan area. Most infections (91%) occurred in people who were hospitalized. To date, EIP surveillance officers have reviewed the medical records of 519 cases. Of these cases:

- **58%** (n=363) had a central venous catheter in the previous 2 days
- **68%** (n=428) had received systemic antibiotics in the 2 weeks before their candidemia episode
- **21%** (n=116) died while hospitalized or within 30 days of candidemia
- 18% (n=115) received TPN in the 14 days before illness onset
- 5% (n=31) had been neutropenic in the previous 2 days

Underlying conditions in past 90 days associated with candidemia cases, January 2011– December 2019, Portland tri-county area (n=630 with chart review completed)

Underlying condition	n (% out of 630)		
Any cancer	104 (16.5%)		
Diabetes	206 (32.7%)		
HIV-related diagnoses	9 (1.4%)		
AIDS (CD4 count <200)	5 (0.8%)		
HIV infection without AIDS	4 (0.6%)		
Any Liver Diagnoses	132 (21.0%)		
Hepatitis C	96 (15.2%)		
Organ transplant	9 (1.4%)		
Pancreatitis	11 (1.7%)		
Any surgery in 90 days prior	178 (28.2%)		
Abdominal surgery	72 (11.4%)		
IV drug use	165 (26.2%)		

The charts to the right displays the distribution of Candida species found in blood isolates from candidemia cases. Currently, 12 different species of Candida have been isolated from blood since January 2011. Of the 674 isolates, 282 isolates were C. albicans (42%). The second most common isolate was C. glabrata (n=168, 25%) and the third most common isolate was C. parapsilosis (n=114, 17%). These three isolates contains 84% (n=564) of the known Candida blood isolates from the tri-county area from 2011-2019. Candida albicans has been the dominant species isolated from bloodstream infections in the tricounty area since the inception of the Oregon EIP candidemia Number of Isolates surveillance in 2011. Since 2011, the number isolates of Candida glabrata has been increasing and we have seen an increase in other species of Candida. We have seen an increase in the number of Candida tropicalis isolates as well as Candida







Candida blood isolates by species and year, Oregon January 2011—December 2019